Laughlin Brady S, Golafshar Michael A, Ahmed Safia, Prince Matthew, Anderson Justin D, Vern-Gross Tamara, Seetharam Mahesh, Goulding Krista, Petersen Ivy, DeWees Todd, Ashman Jonathan B
Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Int J Part Ther. 2022 May 6;9(1):1-11. doi: 10.14338/IJPT-21-00037.1. eCollection 2022 Summer.
Proton beam therapy (PBT) may provide an advantage when planning well-selected patients with extremity soft tissue sarcoma (eSTS), specifically for large, anatomically challenging cases. We analyzed our early experience with PBT on toxicity and outcomes.
A retrospective study was performed for eSTS treated between June 2016 and October 2020 with pencil beam scanning PBT at 2 institutions. Diagnostic, treatment, and toxicity characteristics were gathered from baseline to last follow-up or death. Wound complications were defined as secondary operations for wound repair (debridement, drainage, skin graft, and muscle flap) or nonoperative management requiring hospitalization. Statistical analysis was performed with R software.
Twenty consecutive patients with a median age 51.5 years (range, 19-78 years) were included. Median follow-up was 13.7 months (range, 1.7-48.1 months). Tumor presentation was primary (n = 17) or recurrent after prior combined modality therapy (n = 3). Tumor location was either lower extremity (n = 16) or upper extremity (n = 4). Radiation was delivered preoperatively in most patients (n = 18). Median pretreatment tumor size was 7.9 cm (range, 1.3 -30.0 cm). The 1-year locoregional control was 100%. Four patients (20%) had developed metastatic disease by end of follow-up. Maximum toxicity for acute dermatitis was grade 2 in 8 patients (40%) and grade 3 in 3 patients (15%). After preoperative radiation and surgical resection, acute wound complications occurred in 6 patients (35%). Tumor size was larger in patients with acute wound complications compared with those without (medians 16 cm, range [12-30.0 cm] vs 6.3 cm, [1.3-14.4 cm], = .003).
PBT for well selected eSTS cases demonstrated excellent local control and similar acute wound complication rate comparable to historic controls. Long-term follow-up and further dosimetric analyses will provide further insight into potential advantages of PBT in this patient population.
对于精心挑选的肢体软组织肉瘤(eSTS)患者,尤其是大型、解剖结构复杂的病例,质子束治疗(PBT)可能具有优势。我们分析了我们早期使用PBT治疗的毒性反应和治疗结果。
对2016年6月至2020年10月期间在2家机构接受笔形束扫描PBT治疗的eSTS患者进行了一项回顾性研究。收集从基线到最后一次随访或死亡的诊断、治疗和毒性特征。伤口并发症定义为伤口修复的二次手术(清创、引流、植皮和肌皮瓣)或需要住院治疗的非手术处理。使用R软件进行统计分析。
纳入了20例连续患者,中位年龄51.5岁(范围19 - 78岁)。中位随访时间为13.7个月(范围1.7 - 48.1个月)。肿瘤表现为原发性(n = 17)或先前综合治疗后复发(n = 3)。肿瘤部位为下肢(n = 16)或上肢(n = 4)。大多数患者(n = 18)在术前接受放疗。术前肿瘤中位大小为7.9 cm(范围1.3 - 30.0 cm)。1年局部控制率为100%。4例患者(20%)在随访结束时发生了转移性疾病。急性皮炎的最大毒性反应,8例患者(40%)为2级,3例患者(15%)为3级。术前放疗和手术切除后,6例患者(35%)发生了急性伤口并发症。发生急性伤口并发症患者的肿瘤大小大于未发生者(中位值分别为16 cm,范围[12 - 30.0 cm]和6.3 cm,[1.3 - 14.4 cm],P = .003)。
对于精心挑选的eSTS病例,PBT显示出良好的局部控制,急性伤口并发症发生率与历史对照相似。长期随访和进一步的剂量分析将为PBT在该患者群体中的潜在优势提供进一步的见解。